When do the patents on LYMPHIR expire, and when will biosimilar LYMPHIR enter the market?

Last updated: August 27, 2026

LYMPHIR, or denileukin diftitox-cxdl, is a targeted biologic approved by the U.S. Food and Drug Administration for adults with relapsed or refractory cutaneous T-cell lymphoma, or CTCL, after at least one prior systemic therapy. Citius Pharmaceuticals commercializes LYMPHIR through its subsidiary, Citius Oncology. The product addresses a narrow but medically underserved market, with commercial performance dependent on diagnosis rates, treatment-center adoption, reimbursement, manufacturing reliability, and competition from established CTCL therapies.

Public filings available around the product launch did not yet establish a meaningful LYMPHIR revenue base. The near-term financial profile is therefore launch-driven rather than supported by historical product sales. The principal opportunity is a specialty-oncology product with orphan-disease economics; the principal risk is the small eligible population and the availability of alternative systemic therapies.

What is LYMPHIR approved to treat?

LYMPHIR is approved for adults with relapsed or refractory CTCL who have received at least one prior systemic therapy. CTCL is a group of non-Hodgkin lymphomas involving malignant T cells that primarily affect the skin. The principal commercial subtypes are mycosis fungoides and Sézary syndrome.

The FDA approved LYMPHIR on August 7, 2024. The approval was based on clinical data from Study 302, which evaluated patients with relapsed or refractory CTCL. The FDA label reported an overall response rate of 36%, including a complete response rate of approximately 8%, in the efficacy population. The median duration of response was approximately 7.7 months.[1]

What is the LYMPHIR dosing and treatment burden?

The recommended dose is 9 micrograms per kilogram administered intravenously once daily on days 1 through 5 of a 21-day cycle, for up to eight cycles. Treatment requires repeated infusion-center visits and monitoring for infusion-related reactions, capillary leak syndrome, hepatotoxicity, and other adverse events.[1]

This dosing structure creates both commercial advantages and constraints:

Revenue is generated over multiple treatment cycles rather than through a single administration.
Infusion administration supports hospital and oncology-practice economics.
Five consecutive dosing days can impose logistical burdens on patients and providers.
Adverse-event monitoring may limit use in frail or heavily pretreated patients.

How large is the LYMPHIR market?

The addressable market is small in absolute patient volume but potentially attractive in specialty-pharmaceutical terms. CTCL is a rare disease, and only a subset of diagnosed patients will have relapsed or refractory disease after systemic treatment.

Published epidemiology estimates vary by case definition and geography. U.S. estimates generally place annual CTCL incidence in the low single-digit range per 100,000 people, with prevalence materially higher because many patients have chronic disease. The commercially relevant segment is narrower than total CTCL prevalence because LYMPHIR is indicated only after prior systemic therapy.[2]

A practical market framework is:

Market segment	Commercial relevance for LYMPHIR
All CTCL patients	Broad epidemiological pool
Advanced-stage CTCL	Higher treatment intensity and systemic-therapy use
Relapsed or refractory CTCL	Core labeled population
Patients after at least one systemic therapy	FDA-labeled treatment group
Patients suitable for intravenous therapy	Real-world commercial population
Patients with CD25-expressing malignant cells	Biological rationale for treatment selection

The product’s market penetration will depend on whether physicians use it earlier in the treatment sequence or reserve it for later-line disease. A later-line position limits volume but can support higher treatment urgency and faster adoption among specialist physicians.

What is the competitive landscape for LYMPHIR?

LYMPHIR competes in a fragmented CTCL treatment market rather than against a single dominant product. Relevant alternatives include brentuximab vedotin, mogamulizumab-kpkc, romidepsin, bexarotene, extracorporeal photopheresis, interferon-based regimens, chemotherapy, and investigational therapies.

Therapy	Manufacturer or sponsor	Modality	Primary competitive issue
LYMPHIR	Citius Oncology	Recombinant fusion protein	New commercial entrant with limited post-launch history
Poteligeo	Kyowa Kirin	Anti-CCR4 monoclonal antibody	Established systemic option for relapsed or refractory CTCL
Adcetris	Seagen/Pfizer	Antibody-drug conjugate	Strong oncology infrastructure and CD30-directed positioning
Istodax	Bristol Myers Squibb	HDAC inhibitor	Oral or systemic treatment alternative in relapsed disease
Targretin	Various commercial partners	Retinoid	Established CTCL use, particularly in skin-predominant disease
Extracorporeal photopheresis	Multiple providers	Cell-based procedure	Important option for Sézary syndrome and blood-involved disease
Chemotherapy and immunomodulators	Multiple	Conventional systemic treatment	Lower-cost alternatives and broad physician familiarity

LYMPHIR’s main differentiation is its mechanism. The molecule combines an interleukin-2 receptor-binding domain with diphtheria toxin fragments, enabling targeted delivery of a cytotoxic payload to cells expressing the IL-2 receptor, including CD25-positive malignant T cells.[1]

The competitive position will be stronger in patients who have exhausted or failed common systemic therapies. It will be weaker where physicians prefer oral therapy, established biologics, skin-directed treatment, or therapies with longer real-world experience.

What is the FDA regulatory status and exclusivity outlook for LYMPHIR?

LYMPHIR is FDA-approved under the biologics regulatory framework. The FDA approval applies to the indicated adult CTCL population and does not establish approval for other T-cell malignancies.

The product also received orphan-drug designation for CTCL. Orphan-drug exclusivity generally provides seven years of protection against approval of the same drug for the same disease or condition, subject to statutory exceptions. The expected orphan-exclusivity period would extend into 2031 based on the 2024 approval date, although the precise legal effect depends on the product’s regulatory classification and any applicable FDA determinations.[3]

Biologic exclusivity may also be relevant. A reference biological product approved under the Public Health Service Act can receive 12 years of reference-product exclusivity, but the interaction between biologic exclusivity, prior versions of denileukin diftitox, orphan exclusivity, patents, and potential follow-on products requires product-specific regulatory analysis. The FDA Purple Book, rather than the Orange Book, is the relevant FDA database for biological products.[4]

Does LYMPHIR have Orange Book patents?

No conventional Orange Book listing should be expected because LYMPHIR is a biologic. Patent and regulatory exclusivity analysis should focus on:

FDA Purple Book entries;
biologic reference-product exclusivity;
orphan-drug exclusivity;
issued composition, formulation, manufacturing, and method-of-use patents;
patent-term adjustment and patent-term extension;
potential biosimilar or interchangeable-product pathways.

Publicly available launch materials did not establish a comprehensive, validated patent-number list for LYMPHIR. The commercial barrier may therefore depend more heavily on regulatory exclusivity, manufacturing complexity, clinical know-how, and the narrowness of the indication than on a broad, publicly documented patent thicket.

When does LYMPHIR lose exclusivity?

The clearest statutory exclusivity milestone is the seven-year orphan-drug period associated with the 2024 CTCL approval, subject to FDA interpretation and statutory exceptions. That points to a 2031 timing window for same-drug approval in the same orphan indication.

A separate 12-year biologic-exclusivity analysis could extend the practical protection period toward 2036 if applicable to the approved reference product. That date should not be treated as a confirmed market-entry date because biosimilar approval timing also depends on patent litigation, FDA filing procedures, manufacturing comparability, and the scope of any exclusivity determination.

Protection category	Indicative timing	Commercial implication
FDA approval	August 2024	Launch and start of regulatory exclusivity periods
Orphan-drug exclusivity	Approximately through 2031	Restricts approval of the same drug for the same disease
Potential biologic reference exclusivity	Potentially into 2036	Could delay certain biosimilar approval pathways
Patent protection	Patent-specific	Requires validated patent-family review
Biosimilar market entry	Uncertain	Depends on Purple Book, patents, litigation, and FDA review

What financial trajectory is expected for LYMPHIR?

The financial trajectory is likely to follow four stages.

Launch and market-access phase

The first phase requires payer contracting, treatment-center education, distribution setup, and identification of physicians treating advanced CTCL. Citius Oncology must convert FDA approval into formulary access and reimbursed treatment.

Because CTCL is rare, a national sales organization may not need the scale required for a mass-market drug. The commercial model can focus on academic centers, lymphoma specialists, dermatologists, and selected community oncology practices.

Early revenue ramp

Revenue growth will depend on the number of activated treatment centers and the rate at which patients receive multiple cycles. The product’s intravenous administration may support high gross revenue per treated patient, but net revenue will be reduced by rebates, patient assistance, distributor discounts, and payer concessions.

No established LYMPHIR product-revenue history was available in the launch-period public filings cited here. Consequently, reported earnings cannot yet demonstrate commercial validation. Early indicators should include treated-patient counts, repeat-cycle rates, gross-to-net deductions, payer coverage, and accounts receivable collection.

Scale and profitability phase

LYMPHIR can reach attractive product-level margins if manufacturing yields are stable and commercial infrastructure remains focused. The company’s corporate profitability will depend on selling, general and administrative spending, medical-affairs investment, postmarketing obligations, and the cost of building a specialty oncology franchise.

A simplified revenue model is:

Variable	Low case	Base case	High case
Treated patients	250	750	1,500
Net revenue per patient	$150,000	$200,000	$250,000
Annual product revenue	$37.5 million	$150 million	$375 million

These figures are analytical scenarios, not company guidance. They illustrate the sensitivity of LYMPHIR revenue to patient volume. A rare-disease product can produce substantial revenue with several hundred patients, but the forecast is highly exposed to treatment duration, reimbursement, and physician adoption.

Late-cycle phase

After initial adoption, growth could slow if LYMPHIR remains a later-line therapy. Expansion into additional T-cell malignancies would materially improve the commercial profile, but such expansion would require new clinical evidence and FDA approval. Potential label expansion is therefore an upside option rather than an established revenue source.

What manufacturing and intellectual-property barriers affect LYMPHIR?

LYMPHIR is a recombinant fusion protein requiring biologic manufacturing, purification, quality control, and cold-chain distribution. These requirements are more difficult to replicate than those for a conventional small-molecule generic.

Key barriers include:

cell-line and process development;
control of protein quality attributes;
reproducible toxin-fusion production;
validated analytical methods;
aseptic fill-finish capacity;
comparability data for any follow-on biologic;
clinical and regulatory requirements for biosimilar approval.

Manufacturing risk is commercially important because a supply interruption would affect a small patient population with limited treatment options. The company must also maintain consistency across batches while controlling cost of goods.

Which companies could challenge LYMPHIR?

The most credible competitive threats are established CTCL manufacturers rather than immediate generic entrants. Kyowa Kirin has Poteligeo, while Pfizer’s oncology portfolio includes Adcetris following its acquisition of Seagen. Bristol Myers Squibb has marketed Istodax for peripheral T-cell lymphoma and related oncology settings. Other threats could come from new targeted agents, antibody-drug conjugates, cellular therapies, and clinical-stage treatments for CTCL.

A biosimilar challenge is less likely to be the first commercial threat. The market is small, the product has limited post-approval commercial history, and a follow-on manufacturer would need to justify development economics. The more immediate risk is therapeutic substitution by products with broader labels, established reimbursement, or simpler administration.

What litigation and Paragraph IV risks affect LYMPHIR?

No major Paragraph IV litigation was identified in the launch-period sources cited for LYMPHIR. Paragraph IV litigation is primarily associated with abbreviated new drug applications for small-molecule drugs. For LYMPHIR, the relevant challenge would more likely involve a biosimilar application, patent litigation under the biologics patent framework, or a dispute over regulatory exclusivity.

The litigation risk is therefore currently more dependent on undisclosed or incompletely documented patent families than on a known active generic challenge. Patent diligence should examine composition claims, fusion-protein sequence claims, formulation claims, dosing claims, and methods of treating CTCL or CD25-positive malignancies.

How does LYMPHIR compare with other CTCL biologics?

LYMPHIR has a narrower commercial history than Poteligeo and Adcetris, but it may benefit from its distinct mechanism and a defined relapsed/refractory population.

Factor	LYMPHIR	Poteligeo	Adcetris
Modality	Fusion protein	Monoclonal antibody	Antibody-drug conjugate
CTCL role	Relapsed or refractory disease after systemic therapy	Relapsed or refractory CTCL	CD30-positive disease
Administration	Five consecutive IV dosing days per 21-day cycle	Periodic IV administration	Periodic IV administration
Commercial maturity	Newly launched	Established	Established oncology product
Key differentiation	CD25-directed toxin delivery	CCR4 targeting	CD30 targeting
Main risk	Small market and adoption uncertainty	Competitive overlap	Biomarker and label limitations

What is the investment outlook for LYMPHIR?

LYMPHIR offers Citius Pharmaceuticals a potential recurring product-revenue stream in a specialty market, but the financial outcome depends on execution more than on disease prevalence alone. The investment case improves if the company demonstrates rapid treatment-center activation, durable payer coverage, repeat-cycle treatment, and controlled commercial spending.

The main downside factors are:

slower-than-expected physician adoption;
reimbursement delays;
low treatment persistence;
adverse-event management;
manufacturing or supply problems;
competition from Poteligeo, Adcetris, and emerging CTCL therapies;
dependence on one commercial product;
limited evidence of post-launch demand.

The strongest operating metrics are net sales, treated lives, average revenue per patient, gross margin, cash burn, and the cost of acquiring each prescribing account. Citius’s financial trajectory will be materially more volatile if LYMPHIR revenue is insufficient to offset launch expenses and corporate cash requirements.

Key Takeaways

LYMPHIR is FDA-approved for adults with relapsed or refractory CTCL after at least one prior systemic therapy.
The product entered a rare-disease market with potentially high revenue per patient but limited absolute volume.
Orphan-drug exclusivity points to an approximate 2031 timing window, while biologic exclusivity could be relevant for a longer period.
The FDA Purple Book, not the Orange Book, is the appropriate regulatory reference for LYMPHIR.
No major Paragraph IV challenge was identified in the launch-period public sources reviewed.
The principal competitive threats are established CTCL therapies, not conventional small-molecule generics.
Revenue forecasts are highly sensitive to patient volume, treatment persistence, payer access, and net pricing.
Manufacturing complexity supports a barrier to entry but does not replace validated patent and regulatory exclusivity.
Citius Oncology’s financial trajectory depends on converting FDA approval into repeat-cycle commercial use while controlling launch costs.

FAQs About LYMPHIR Market Dynamics

Is LYMPHIR a chemotherapy drug?

LYMPHIR is a recombinant fusion protein that delivers a diphtheria toxin-derived cytotoxic payload to cells expressing the interleukin-2 receptor. It is not a conventional cytotoxic chemotherapy.

Does LYMPHIR have a biosimilar competitor?

No established biosimilar competitor was identified in the launch-period public sources cited here. Any future biosimilar challenge would depend on FDA eligibility, regulatory exclusivity, patents, and development economics.

What is the most important commercial risk for LYMPHIR?

The largest commercial risk is the limited size of the eligible CTCL population combined with competition from established systemic therapies.

Can LYMPHIR be used for leukemia or other lymphomas?

The FDA approval discussed here is for relapsed or refractory CTCL. Use in other malignancies would require supporting evidence and, where applicable, separate FDA approval.

Which metrics should investors monitor after launch?

Investors should monitor net product revenue, treated-patient volume, repeat-cycle rates, gross-to-net adjustments, payer coverage, gross margin, cash burn, and commercial-account growth.

References

U.S. Food and Drug Administration. (2024). LYMPHIR (denileukin diftitox-cxdl) prescribing information. FDA.
National Cancer Institute. (2024). Cutaneous T-cell lymphoma. National Cancer Institute.
U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. FDA.
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
Citius Pharmaceuticals, Inc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission.

Established Pharmacologic Class	CD25-directed Cytotoxin
Chemical Structure	Diphtheria Toxin Interleukin-2 Recombinant Fusion Proteins

LYMPHIR Drug Profile

Summary for Tradename: LYMPHIR

Pharmacology for LYMPHIR

Note on Biologic Patents

1) High Certainty: US Patents for LYMPHIR Derived from Brand-Side Litigation

2) High Certainty: US Patents for LYMPHIR Derived from DrugPatentWatch Analysis and Company Disclosures

3) Low Certainty: US Patents for LYMPHIR Derived from Patent Text Search

LYMPHIR Market Dynamics and Financial Trajectory: FDA Status, Commercial Opportunity, Competition, and Revenue Outlook